J. Mark Jackson, MD, FAAD, Senior Vice President, Clinical Development for Evommune, discusses the importance of improved efficacy and safety for underserved patients with atopic dermatitis.
advertisement
Evolving Atopic Dermatitis Therapeutic Capabilities
Share
SaveShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
J. Mark Jackson, MD, FAAD, Senior Vice President, Clinical Development for Evommune, discusses the importance of improved efficacy and safety for underserved patients with atopic dermatitis.
Title
Program Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?